The special case of gene therapy pricing
暂无分享,去创建一个
[1] T. Brennan,et al. New expensive treatments for hepatitis C infection. , 2014, JAMA.
[2] Josh Tycko,et al. Lessons learned from the clinical development and market authorization of Glybera. , 2013, Human gene therapy. Clinical development.
[3] K. High,et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. , 2012, Blood.
[4] Pratima Chowdary,et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.
[5] A. Kesselheim. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. , 2011, The Milbank quarterly.
[6] R. Samulski,et al. Recombinant adeno-associated virus: clinical application and development as a gene-therapy vector. , 2012, Therapeutic delivery.
[7] S. Pai,et al. Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] Kathleen A. Marshall,et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.
[9] E. Berndt,et al. Vaccine advance-purchase agreements for low-income countries: practical issues. , 2005, Health affairs.
[10] Scott Stern,et al. Innovation Policy and the Economy 2014 , 2009 .
[11] S. Orkin,et al. Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases , 2009, Genome Medicine.